| Literature DB >> 27210746 |
Zsolt Sebestyen1, Wouter Scheper1, Anna Vyborova1, Siyi Gu2, Zuzana Rychnavska1, Marleen Schiffler1, Astrid Cleven1, Coraline Chéneau1, Martje van Noorden1, Cassie-Marie Peigné3, Daniel Olive4, Robert Jan Lebbink5, Rimke Oostvogels2, Tuna Mutis2, Gerrit Jan Schuurhuis6, Erin J Adams7, Emmanuel Scotet3, Jürgen Kuball8.
Abstract
Human Vγ9Vδ2 T cells respond to tumor cells by sensing elevated levels of phosphorylated intermediates of the dysregulated mevalonate pathway, which is translated into activating signals by the ubiquitously expressed butyrophilin A1 (BTN3A1) through yet unknown mechanisms. Here, we developed an unbiased, genome-wide screening method that identified RhoB as a critical mediator of Vγ9Vδ2 TCR activation in tumor cells. Our results show that Vγ9Vδ2 TCR activation is modulated by the GTPase activity of RhoB and its redistribution to BTN3A1. This is associated with cytoskeletal changes that directly stabilize BTN3A1 in the membrane, and the subsequent dissociation of RhoB from BTN3A1. Furthermore, phosphoantigen accumulation induces a conformational change in BTN3A1, rendering its extracellular domains recognizable by Vγ9Vδ2 TCRs. These complementary events provide further evidence for inside-out signaling as an essential step in the recognition of tumor cells by a Vγ9Vδ2 TCR.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27210746 PMCID: PMC5035041 DOI: 10.1016/j.celrep.2016.04.081
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423